|
Age, Mean (SD)
|
49.9 (11.6)
|
48.4 (11.6)
|
0.015
|
|
Age Category, n (%)
|
|
|
0.190
|
|
18–24
|
10 (1.3) |
10 (1.3) |
|
25–34
|
89 (11.2) |
100 (12.6) |
|
35–49
|
246 (31.0) |
283 (35.6) |
|
50–64
|
385 (48.5) |
348 (43.8) |
|
65+
|
64 (8.1) |
53 (6.7) |
|
Female, n (%)
|
211 (26.6)
|
209 (26.3)
|
0.909
|
|
Race, n (%)
|
|
|
0.134
|
|
African American
|
339 (42.7)
|
293 (36.9)
|
|
Asian
|
2 (0.3)
|
2 (0.3)
|
|
Caucasian
|
393 (49.5)
|
434 (54.7)
|
|
Other/Unknown
|
60 (7.6)
|
65 (8.2)
|
|
Region, n (%)
|
|
|
0.560
|
|
Midwest
|
271 (34.1)
|
279 (35.1)
|
|
South
|
277 (34.9)
|
249 (31.4)
|
|
West
|
41 (5.2)
|
50 (6.3)
|
|
Northeast
|
144 (18.1)
|
156 (19.6)
|
|
Other/Unknown
|
61 (7.7)
|
60 (7.6)
|
|
Plan Type, n (%)
|
|
|
0.001
|
|
Commercial
|
93 (11.7)
|
163 (20.5)
|
|
Medicaid
|
74 (9.3)
|
65 (8.2)
|
|
Medicare
|
69 (8.7)
|
55 (6.9)
|
|
Othera
|
132 (16.6)
|
158 (19.9)
|
|
Missing
|
426 (53.7)
|
353 (44.5)
|
|
Index Year, n (%)
|
|
|
0.026
|
|
2016
|
454 (57.2)
|
410 (51.6)
|
|
2017
|
269 (33.2)
|
285 (35.9)
|
|
2018
|
71 (8.9)
|
99 (12.5)
|
|
Baseline Weight, Mean (SD)
|
82.2 (20.6)
|
83.2 (19.9)
|
0.326
|
|
Baseline BMI, Mean (SD)
|
27.6 (6.9)
|
27.9 (6.9)
|
0.410
|
|
Baseline BMI Category, n (%)
|
|
|
0.247
|
|
Underweight (BMI <18.5)
|
18 (2.3) |
25 (3.1)
|
|
Normal (BMI 18.5–24.9)
|
304 (38.3)
|
269 (33.9)
|
|
Overweight (BMI 25.0–29.9)
|
243 (30.6)
|
261 (32.9)
|
|
Obese (BMI ≥30)
|
229 (28.8)
|
239 (30.1)
|
|
Baseline Comorbidities
|
|
|
|
QCI Score, Mean (SD)
|
3.3 (0.03)
|
3.4 (0.03)
|
0.337
|
|
Individual Conditions, n (%)
|
|
|
|
Prediabetes/Glucose Intolerance
|
12 (1.5)
|
9 (1.1)
|
0.510
|
|
T2DM
|
94 (11.8)
|
93 (11.7)
|
0.938
|
|
MI
|
33 (4.2)
|
21 (2.6)
|
0.097
|
|
PVD
|
9 (1.1)
|
11 (1.4)
|
0.653
|
|
CHF
|
26 (3.3)
|
22 (2.8)
|
0.558
|
|
Hypertension
|
234 (29.5)
|
244 (30.7)
|
0.584
|
|
Hyperlipidemia
|
149 (18.8)
|
155 (19.5)
|
0.702
|
|
Obesity
|
220 (27.7)
|
236 (29.7)
|
0.375
|
|
NASH
|
14 (1.8)
|
17 (2.1)
|
0.586
|
|
AIDS
|
492 (62.0)
|
521 (65.6)
|
0.130
|
|
Cancer
|
56 (7.1)
|
51 (6.4)
|
0.617
|
|
Prior Medication Use, n (%)
|
|
|
|
Diabetes Therapies
|
69 (8.7)
|
68 (8.6)
|
0.929
|
|
Psychiatric/Neurologic Therapies
|
130 (16.4)
|
152 (19.1)
|
0.149
|
|
Steroid Hormone
|
122 (15.4)
|
129 (16.2)
|
0.630
|
|
Hormone Therapy/Contraception
|
10 (1.3)
|
14 (1.8)
|
0.411
|
|
Appetite Stimulants/Suppressants
|
12 (1.5)
|
16 (2.0)
|
0.446
|
|
Antihypertensives
|
101 (12.7)
|
108 (13.6)
|
0.603
|
|
Index Regimen
|
|
|
|
PI Regimen Type, n (%)
|
|
|
|
DRV-Basedb
|
409 (51.5)
|
N/A
|
N/A
|
|
ATV-Based
|
256 (32.2)
|
N/A
|
N/A
|
|
Other PI-Based Regimens
|
129 (16.2)
|
N/A
|
N/A
|
|
PI with Booster, n (%)c
|
739 (93.1) |
N/A
|
N/A
|
| INSTI Regimen Type, n (%) |
|
|
|
|
BIC-Based
|
N/A
|
7 (0.9)
|
N/A
|
|
DTG-Basedd
|
N/A
|
349 (44.0)
|
N/A
|
|
EVG-Based
|
N/A
|
385 (48.5)
|
N/A
|
|
RAL-Based
|
N/A
|
53 (6.7)
|
N/A
|
|
TAF Containing, n (%)
|
19 (2.4)
|
221 (27.8)
|
N/D
|